STERIS plc has been deemed one of the overlooked dividend stocks to consider purchasing. Anticipation is building for the next quarter's earning report in 2025. Various analysts have been discussing the stock, with the recovery of AST leading to an upgrade to a 'Strong Buy'. A conference call is to be hosted regarding the full year fiscal results for 2025. The Q3 2024 earnings call revealed a surprise in revenue. It's an opportune period to examine the stock, despite a cautious health care sentiment. Protections on shareholder returns are escalating. Jim Cramer labels it as 'just a strong company'. The Q3 report indicated Revenue of $1.4 billion, surpassing expectations. There's a settlement reached in Ethylene Oxide Litigation. The surgical equipment arm of the business has outperformed the market's expectations, while the renal business is sold off for $196 million.In terms of management, there are board changes and a CEO succession plan underway. The company also acquired two other entities valued at $225 million. The stock received an 'average' rating of moderate buy from multiple brokerages. Yet, Raymond James downgraded the stock to a 'hold' status.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Mon, 28 Apr 2025 09:53:44 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor -2
